1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Tactile Systems Technology's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was -132.52%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Tactile Systems Technology's 1-Year ROIIC % or its related term are showing as below:
TCMD's 1-Year ROIIC % is ranked worse than 85.56% of 824
companies
in the Medical Devices & Instruments industry
Industry Median: 0.38
vs TCMD: -132.52
Tactile Systems Technology (NAS:TCMD) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Tactile Systems Technology 1-Year ROIIC % Related Terms
Tactile Systems Technology 1-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCMD vs SSII, BVS, BBNX: 1-Year ROIIC % Comparison
For the Medical Devices subindustry, Tactile Systems Technology's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tactile Systems Technology 1-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tactile Systems Technology's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Tactile Systems Technology's 1-Year ROIIC % falls into.
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( 19.5048 (Mar. 2026) - 15.0136 (Mar. 2025) )
/
( 153.054 (Mar. 2026) - 156.443 (Mar. 2025) )
=
4.4912
/
-3.3890000000001
=
-132.52%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Tactile Systems Technology (TCMD) has a 1-Year ROIIC % of -132.52 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Tactile Systems Technology and its competitors. According to the industry distribution chart, Tactile Systems Technology ranks #705 out of 824 companies in the Medical Devices & Instruments industry, placing it in the top 85.6%.
Is Tactile Systems Technology's 1-Year ROIIC % too high?
Tactile Systems Technology's current 1-Year ROIIC % is -132.52. Based on the distribution chart, Tactile Systems Technology ranks #705 out of 824 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tactile Systems Technology has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tactile Systems Technology's 1-Year ROIIC % compare to SSII and BVS?
According to the Medical Devices & Instruments industry distribution chart, Tactile Systems Technology ranks #705 out of 824 companies for 1-Year ROIIC %. This places Tactile Systems Technology in the lower half of its industry. The industry median 1-Year ROIIC % is 0.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Medical Devices & Instruments company?
The median 1-Year ROIIC % among Medical Devices & Instruments companies is 0.38, based on 824 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Tactile Systems Technology and its competitors. For the Medical Devices & Instruments industry, the median 1-Year ROIIC % is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tactile Systems Technology's current 1-Year ROIIC % is -132.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tactile Systems Technology stock overvalued right now?
Based on GuruFocus' analysis, Tactile Systems Technology (TCMD) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.74, compared to a current price of $30.64 — trading 63.5% above its estimated fair value. The current 1-Year ROIIC % is -132.52. Tactile Systems Technology's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Tactile Systems Technology (TCMD), the current 1-Year ROIIC % is -132.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tactile Systems Technology (TCMD) Overvalued in 2026?
Based on GuruFocus' analysis, Tactile Systems Technology stock appears to be overvalued.
The current stock price of $30.64 is trading 63.5% above its estimated GF Value™ of $18.74.
GuruFocus considers Tactile Systems Technology to be Significantly Overvalued.
Key valuation signals for TCMD:
1-Year ROIIC %: -132.52
GF Value™: $18.74 vs. price of $30.64 (63.5% above fair value)
No single metric tells the full story. See the TCMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
74GF Score
Get the complete analysis for TCMD
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCMD has been successfully added to your 
